The CARE-in-HEALTH project has marked a highly productive week, achieving two important milestones in advancing the understanding of chronic lipid-driven vascular inflammation.

In recent days, biosensor user testing sessions were conducted in collaboration with the teams from i3S – Instituto de Investigação e Inovação em Saúde and Seqvera Ltd. Oy. These sessions provided valuable feedback, contributing to the ongoing refinement and optimization of the technology developed within the project.

At the same time, the project officially launched its Resolvin clinical trial, aimed at evaluating the effects of omega-3 on lipid profiles. This represents a significant step toward translating scientific discoveries into tangible health outcomes.

The week also provided an opportunity to strengthen collaboration among European partners, who gathered at the Istituto Mario Negri. Bringing together teams from Portugal, Italy, and Finland, the meeting highlighted the strong cross-European cooperation at the core of CARE-in-HEALTH.

These achievements reflect the project’s continued momentum and its commitment to advancing cardiovascular research at the European level.

We recently hosted our consortium meeting as part of the Horizon Europe project CARE-IN-HEALTH, bringing together 10 European partners: INSERM, Karolinska Institutet, i3S – Instituto de Investigação e Inovação em Saúde Seqvera Ltd. Oy, Qlucore, University of Strasbourg, INESC TEC, Istituto Mario Negri, Syddansk Universitet – University of Southern Denmark, Inserm Transfert, Universite de Lorraine

Exciting results were presented on the role of inflammation resolution in cardiovascular diseases, opening new avenues for cardiovascular health research.

The presence of our SAB members Professor Faiez Zannad and Professor Charles N. Serhan enriched the discussions, fostering constructive and inspiring exchanges among researchers and project partners.

Meetings like this strengthen our commitment to advancing collaborative European research and turning scientific knowledge into tangible benefits for patients.